VEA
APLS

Virtus ETF Advisers’s Apellis Pharmaceuticals APLS Stock Holding History

Virtus ETF Advisers’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,680
Closed -$341K – 444
2024
Q4 		$341K Buy
10,680
+2,942
+38% +$88.5K 0.14% 215
2024
Q3 		$223K Hold
7,738
– – 0.1% 245
2024
Q2 		$297K Buy
7,738
+436
+6% +$19.7K 0.15% 230
2024
Q1 		$429K Buy
7,302
+1,051
+17% +$67K 0.23% 189
2023
Q4 		$374K Buy
6,251
+2,950
+89% +$150K 0.24% 176
2023
Q3 		$126K Sell
3,301
-429
-12% -$18.8K 0.08% 319
2023
Q2 		$340K Sell
3,730
-2,117
-36% -$183K 0.2% 167
2023
Q1 		$386K Buy
5,847
+104
+2% +$6K 0.21% 149
2022
Q4 		$297K Sell
5,743
-313
-5% -$16.6K 0.16% 270
2022
Q3 		$414K Buy
6,056
+86
+1% +$5.09K 0.17% 225
2022
Q2 		$270K Sell
5,970
-2,755
-32% -$126K 0.1% 279
2022
Q1 		$443K Hold
8,725
– – 0.2% 138
2021
Q4 		$413K Buy
8,725
+1,673
+24% +$65.9K 0.16% 137
2021
Q3 		$232K Sell
7,052
-641
-8% -$36K 0.1% 229
2021
Q2 		$486K Buy
7,693
+1,932
+34% +$99.7K 0.2% 156
2021
Q1 		$247K Buy
5,761
+93
+2% +$4.4K 0.1% 291
2020
Q4 		$324K Sell
5,668
-4,279
-43% -$181K 0.13% 189
2020
Q3 		$300K Sell
9,947
-1,352
-12% -$40.4K 0.16% 223
2020
Q2 		$369K Sell
11,299
-1,697
-13% -$54.5K 0.17% 239
2020
Q1 		$348K Sell
12,996
-1,892
-13% -$67.2K 0.14% 209
2019
Q4 		$456K Buy
14,888
+2,953
+25% +$81.7K 0.07% 215
2019
Q3 		$288K Sell
11,935
-665
-5% -$18.3K 0.06% 201
2019
Q2 		$319K Sell
12,600
-1,738
-12% -$35.4K 0.07% 199
2019
Q1 		$280K Sell
14,338
-1,568
-10% -$24.7K 0.6% 64
2018
Q4 		$210K Sell
15,906
-4,989
-24% -$76.5K 0.04% 176
2018
Q3 		$372K Sell
20,895
-15,328
-42% -$283K 0.04% 172
2018
Q2 		$797K Buy
+36,223
New +$832K 0.7% 29

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtus ETF Advisers's APLS Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Apellis Pharmaceuticals (APLS) in Q1 2025, closing a stake of 10,680 shares — an estimated $341K sold.

Virtus ETF Advisers first reported a position in APLS in Q2 2018 and held it in 27 quarters. The position peaked at $797K in Q2 2018. 255 funds tracked by Wall St. Rank hold APLS as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Apellis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 10,680 Apellis Pharmaceuticals shares in Q1 2025, an estimated $341K.
  • Virtus ETF Advisers first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 27 quarters.
  • Virtus ETF Advisers's Apellis Pharmaceuticals position peaked at $797K in Q2 2018.
  • 255 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.